Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 1
2012 1
2013 2
2014 1
2015 3
2016 1
2017 2
2018 3
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. Gamucci T, et al. Among authors: fabbri ma. Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7. Cancer Biol Ther. 2019. PMID: 30403909 Free PMC article.
Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A, Pompei L, D'Auria G, Pofi E, Ruggeri EM. Moscetti L, et al. Among authors: agnese fabbri m. Tumori. 2015 Sep-Oct;101(5):469-73. doi: 10.5301/tj.5000376. Epub 2015 Jun 13. Tumori. 2015. PMID: 26108239
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P. Pizzuti L, et al. Among authors: fabbri ma. Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16. Cancer Biol Ther. 2018. PMID: 29336662 Free PMC article.
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study.
Gagno S, D'Andrea MR, Mansutti M, Zanusso C, Puglisi F, Dreussi E, Montico M, Biason P, Cecchin E, Iacono D, Russo S, Cinausero M, Saracchini S, Gasparini G, Sartori D, Bari M, Collovà E, Meo R, Merkabaoui G, Spagnoletti I, Pellegrino A, Gianni L, Sandri P, Cretella E, Vattemi E, Rocca A, Serra P, Fabbri MA, Benedetti G, Foghini L, Medici M, Basso U, Amoroso V, Riccardi F, Baldelli AM, Clerico M, Bonura S, Saggia C, Innocenti F, Toffoli G. Gagno S, et al. Among authors: fabbri ma. Clin Breast Cancer. 2019 Apr;19(2):137-145.e4. doi: 10.1016/j.clbc.2018.11.009. Epub 2018 Nov 24. Clin Breast Cancer. 2019. PMID: 30584056 Free article.
Should We Use Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer After Radical Cystectomy?
Ruggeri EM, Fabbri MA, Nelli F. Ruggeri EM, et al. Among authors: fabbri ma. J Clin Oncol. 2016 Sep 10;34(26):3223. doi: 10.1200/JCO.2016.67.5132. Epub 2016 Jul 11. J Clin Oncol. 2016. PMID: 27400940 No abstract available.
ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study.
Moscetti L, Mentuccia L, Vici P, Quadrini S, Sperduti I, Pizzuti L, Fabbri MA, Vaccaro A, Maugeri-Saccà M, Barba M, Sergi D, Zampa G, Gamucci T. Moscetti L, et al. Among authors: fabbri ma. Future Oncol. 2017 Jul;13(17):1517-1525. doi: 10.2217/fon-2017-0062. Epub 2017 Apr 21. Future Oncol. 2017. PMID: 28429617 Clinical Trial.
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.
Moscetti L, Fabbri MA, Natoli C, Vici P, Gamucci T, Sperduti I, Iezzi L, Iattoni E, Pizzuti L, Roma C, Vaccaro A, D'Auria G, Mauri M, Mentuccia L, Grassadonia A, Barba M, Ruggeri EM. Moscetti L, et al. Among authors: fabbri ma. Oncotarget. 2017 Apr 20;8(33):54528-54536. doi: 10.18632/oncotarget.17262. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903361 Free PMC article.
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M. Ganzinelli M, et al. Among authors: fabbri ma. Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331. Sci Rep. 2015. PMID: 26573509 Free PMC article. Clinical Trial.
Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey.
Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A, Seminara P, Longo F, Gori S, Vici P, Gamucci T, Mauri M, Laudadio L, Nuzzo A, Fabbri MA, Fattoruso SI, Mazzilli L, Grassadonia A, Cianchetti E, Natoli C. Tinari N, et al. Among authors: fabbri ma. Clin Breast Cancer. 2015 Apr;15(2):e131-7. doi: 10.1016/j.clbc.2014.10.005. Epub 2014 Oct 22. Clin Breast Cancer. 2015. PMID: 25454738 Free article.
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors.
Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Aglianò AM, Cristofanilli M. Gazzaniga P, et al. Among authors: fabbri ma. Int J Cancer. 2010 May 15;126(10):2437-47. doi: 10.1002/ijc.24953. Int J Cancer. 2010. PMID: 19821489 Free article. Clinical Trial.
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback